Abstract:Noha Nafee, 1, 2 Dina M Gaber, 3 Alaa Abouelfetouh, 4, 5 Mustafa Alseqely, 4 Martin Empting, 6 Marc Schneider 7 1 Department of Pharmaceutics, College of Pharmacy, Kuwait University, Safat, 13110, Kuwait; 2 Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; 3 Department of Pharmaceutics, Division of Pharmaceutical Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, 1029, Egypt; 4 Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; 5 Department of Microbiology and Immunology, Faculty of Pharmacy, Alamein International University, Alamein, 5060335, Egypt; 6 Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Department of Antiviral and Antivirulence Drugs (AVID), Saarland University, Saarbrücken, 66123, Germany; 7 Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, 66123, Germany Correspondence: Noha Nafee, Department of Pharmaceutics, College of Pharmacy, Kuwait University, Safat, 13110, Kuwait, Tel +96524634914 ; +96560300583, Fax +96524636843, Email Introduction: Cystic fibrosis (CF) is associated with pulmonary Pseudomonas aeruginosa infections persistent to antibiotics. Methods: To eradicate pseudomonal biofilms, solid lipid nanoparticles (SLNs) loaded with quorum-sensing-inhibitor (QSI, disrupting bacterial crosstalk), coated with chitosan (CS, improving internalization) and immobilized with alginate lyase (AL, destroying alginate biofilms) were developed. Results: SLNs (140– 205 nm) showed prolonged release of QSI with no sign of acute toxicity to A549 and Calu-3 cells. The CS coating improved uptake, whereas immobilized-AL ensured > 1.5-fold higher uptake and doubled SLN diffusion across the artificial biofilm sputum model. Respirable microparticles comprising SLNs in carbohydrate matrix elicited aerodynamic diameters MMAD (3.54, 2.48 μm) and fine-particle-fraction FPF (65, 48%) for anionic and cationic SLNs, respectively. The antimicrobial and/or antibiofilm activity of SLNs was explored in Pseudomonas aeruginosa reference mucoid/nonmucoid strains as well as clinical isolates. The full growth inhibition of planktonic bacteria was dependent on SLN type, concentration, growth medium, and strain. OD measurements and live/dead staining proved that anionic SLNs efficiently ceased biofilm formation and eradicated established biofilms, whereas cationic SLNs unexpectedly promoted biofilm progression. AL immobilization increased biofilm vulnerability; instead, CS coating increased biofilm formation confirmed by 3D-time lapse confocal imaging. Incubation of SLNs with mature biofilms of P. aeruginosa isolates increased biofilm density by an average of 1.5-fold. CLSM further confirmed the binding and uptake of the labeled SLNs in P. aeruginosa biofilms. Considerable uptake of CS-coated SLNs in non-mucoid strains could be observed presumably due to interaction of chitosan with LPS glycolipids in the outer cell membrane of P. aeruginosa . Conclusion: The biofilm-destructive potential of QSI/SLNs/AL inhalation is promising for site-specific biofilm-targeted interventional CF therapy. Nevertheless, the intrinsic/extrinsic fundamentals of nanocarrier–biofilm interactions require further investigation. Keywords: alginate lyase, chitosan, solid lipid nanoparticles, cystic fibrosis, Pseudomonas aeruginosa , quorum-sensing inhibitors Around 75% of adult cystic fibrosis (CF) patients suffer from the invasion of mucoid, alginate-producing strains of Pseudomonas aeruginosa that wreaks havoc upon the airways leading to accelerated deterioration of pulmonary function and ending in substantial morbidity. 1 The mucoid phenotype of P. aeruginosa – being pathognomonic for the disease – poses multiple challenges to effective treatment. Pathogenicity traits allowing P. aeruginosa to endure, proliferate, and profoundly affect all stages of CF pulmonary disease can be predicated by multiple virulence factors and biofilm formation. In addition to the mechanical stability of mature P. aeruginosa biofilms persisting in the respiratory tract, alginate overproduction is involved in the establishment of microcolonies at the beginning of biofilm formation, in addition to mechanical stability of mature P. aeruginosa biofilms persisting in the respiratory tract. P. aeruginosa biofilm is a self-produced matrix of polysaccharides (eg, alginate), proteins, nuclei -Abstract Truncated-

Diagnosis of biofilm infections in cystic fibrosis patients

Pseudomonas aeruginosa in the Cystic Fibrosis Lung

Antibiofilm activity of Prevotella species from the cystic fibrosis lung microbiota against Pseudomonas aeruginosa

Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis

Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm

Informed development of a multi‐species biofilm in chronic obstructive pulmonary disease

Altering the interfacial rheology of Pseudomonas aeruginosa and Staphylococcus aureus with N-acetyl cysteine and cysteamine

Bacterial Biofilm and its Role in the Pathogenesis of Disease

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis

Biofilm Production and Its Implications in Pediatrics

Pseudomonas aeruginosa senses and responds to epithelial potassium flux via Kdp operon to promote biofilm

Challenges in Laboratory Detection of Fungal Pathogens in the Airways of Cystic Fibrosis Patients

Aspergillus Fumigatus Biofilm on Primary Human Sinonasal Epithelial Culture

Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis

Periodontal condition and periodontal risk assessment in adult patients with cystic fibrosis

Mucin adhesion of serial cystic fibrosis airways Pseudomonas aeruginosa isolates

Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?

Fungal Colonization of the Airways of Patients with Cystic Fibrosis: the Role of the Environmental Reservoirs

Adaptive Interactions of Achromobacter spp. with Pseudomonas aeruginosa in Cystic Fibrosis Chronic Lung Co-Infection

16S rRNA gene sequencing reveals site-specific signatures of the upper and lower airways of cystic fibrosis patients

Interplay of Mycobacterium abscessus and Pseudomonas aeruginosa in coinfection: Biofilm Dynamics and Host Immune Response